DALLAS, Oct. 24, 2022 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. TSHAa patient-centric, key-stage gene therapy company focused on the development and commercialization of AAV-based gene therapies for the treatment of monogenic central nervous system (CNS) disorders in both rare and large patient populations, announced today that it will host a conference call and a Webcast with slides discussing Astellas Pharma’s strategic investment to support the development of two of Taysha’s AAV-based gene therapy programs, TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy (GAN), on Tuesday, October 25th, 2022 , at 8:00 p.m. Eastern Time.
About Taysha gene therapies
Taysha gene therapies TSHA has set itself the task of eradicating monogenic CNS diseases. With a unique focus on curative drug development, we aim to quickly transfer our treatments from the bench to the bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with UT Southwestern’s world-class gene therapy program to build a comprehensive AAV gene therapy pipeline focused on both rare and large market indications. Together, we leverage our fully integrated platform – an engine for potential new medicines – with the aim of dramatically improving patients’ lives. For more information, see www.tayshagtx.com.
Company contact:
Kimberly Lee, DO
Chief Corporate Affairs Officer
Taysha gene therapies
klee@tayshagtx.com
Media contact:
Caroline Hawley
Invoke Canale
carolyn.hawley@evokegroup.com
[ad_2]
Source story
